Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome

Abstract

The role of drug therapy in the treatment of the sleep apnea/hypopnea syndrome is unclear. In a randomised, double-blind, placebo-controlled study, we investigated the value of 14-day therapy with protriptyline (20 mg daily) or actazolamide (250 mg 4 times per day) on symptoms and on the frequency of apneas, hypopneas, arousals, adn 4% desaturations in 10 patients with obstructive sleep apnea/hypopnea syndrome. Overall, protriptyline did not have a significant effect either on symptoms or on any of the above polysomnographic criteria. Acetazolamide reduced the apnea/hypopnea frequency [placebo 50 ± 26 (SD); acetazolamide 26 ± 20/h of sleep, p < 0.03] and tended to decrease the frequency of 4% desaturations (placebo 29 ± 20; acetazolamide 19 ± 16/h of sleep, p = 0.06). Despite these physiological improvements, acetazolamide did not significantly improve symptoms and paraesthesiae were common. Contrary to earlier studies, we conclude that protriptyline may have a limited role in the treatment of the sleep apnea syndrome. The reason why acetazolamide produced a physiological, but not a symptomatic, response requires further investigation.